Please assess the completion status of the following clinical trial:

Trial Title: PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Hospitalized or will be hospitalized prior to randomization for the treatment of severe COVID-19 with SARS-CoV-2 infection confirmed by either a) a positive reverse transcriptase polymerase chain reaction (RT PCR) or b) an antigen-based test from any respiratory, nasopharyngeal, saliva, blood, or stool specimen at Screening or documented within 1 week prior to the start of Screening (Severe COVID-19 is defined as confirmed disease in patients who are hospitalized with hypoxia \[SpO2 ≤93% on room air\], respiratory rate \>30, PaO2/FiO2 \<300, but do not require IMV).~2. Age ≥ 18 years~3. Platelet count ≥ 50,000/µL~4. If fertile, willing to use effective birth control methods during the study~5. Provision of informed consent within 96 hours after hospitalization~Exclusion Criteria:~1. In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments~2. Currently intubated or intubated between screening and randomization~3. Suspected active uncontrolled bacterial, fungal, viral, or other infection (besides COVID 19)~4. Prior allogenic hematopoietic stem cell transplantation~5. Active lung cancer or history of lung cancer within the past 12 months~6. Any active grade 2 or higher hemorrhage~7. Any active gastrointestinal or metabolic condition that could interfere with absorption of oral medication~8. Uncontrolled intercurrent illness that, in the judgment of the treating physician, would limit compliance with study requirements~9. Known seropositivity for human immunodeficiency virus with cluster of differentiation 4 (CD4) count \< 200/mm3 within 3 months prior to randomization~10. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination~11. Concurrent enrollment in another interventional trial (investigational COVID-19 antiviral studies are permitted)~12. Serum creatinine \> 2.5 mg/dL~13. Total bilirubin \> 4× the upper limit of normal~14. QT corrected by the Fridericia method (QTcF) prolongation \> 480 msec~15. Known history of New York Heart Association Class II, III, or IV congestive heart failure prior to hospital admission~16. Known allergic reaction to any Janus kinase 2 (JAK2) inhibitor~17. Exposure to any JAK2 inhibitor within 28 days~18. Currently receiving a strong CYP3A4 inhibitor or strong P450 inducer (Appendix 1 and Appendix 2, respectively) and unable to stop the medication prior to the first dose of study drug and throughout the duration of study drug administration~19. Treatment with cytoreductive chemotherapy administered within 14 days prior to randomization~20. Administration of an IL 1 or IL 6 blocking immunomodulatory agent (such as tocilizumab, canakinumab, sarilumab, anakinra) within 48 hours prior to randomization~21. Currently receiving therapeutic anticoagulation or anti platelet medication and unable to stop the medication prior to randomization. Prophylactic anticoagulation therapy or aspirin (≤ 100mg) are permitted.~22. Unable to ingest capsules or tablets at randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pacritinib and SOC (Type: EXPERIMENTAL): Pacritinib 400 mg once daily \[QD\] on Day 1, then 200 mg twice daily \[BID\] from Day 2 to Day 14) + SOC
- Placebo and SOC (Type: PLACEBO_COMPARATOR): 4 capsules once daily \[QD\] on Day 1, then 2 capsules twice daily \[BID\] from Day 2 to Day 14) + SOC

Based on this trial design, predict the completion outcome and termination type (if applicable).